Report: Gamida cites success in leukemia PhIII

Globes is reporting that Gamida Cell completed a positive Phase III study if its stem cell treatment for leukemia and lymphoma. Investigators say that a preliminary analysis found that the therapy hit its primary outcome on the mortality rate. Secondary endpoints should be ready soon. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.